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Abstract
Introduction
 Adulthood obesity is one of the most common, costly and 
preventable diseases the world is experiencing today 
(Center for Disease Control and Prevention, [CDC], 2017).
 While obesity can be related to socioeconomic status and race, it is 
ultimately nondiscriminatory. Roughly 40% of Americans were 
obese as of 2016, whereas only 30% were in 2000 (National Center 
for Health Statistics, [NCHS], 2017).  
 From this statistic it can be extrapolated that 32.75 million more 
Americans were diagnosed with obesity in 16 years, or 3-4 people 
every minute.
 The purpose of this study is to determine the most effective 
treatment method available today to combat this rising epidemic.





 Pharmacotherapies such as phentermine and orlistat, and weight 
loss surgeries such as gastric bypass and sleeve gastrectomy are 
valuable tools to treat obesity. They show increased weight loss 
results, and this helps patients to continue their weight loss efforts. 
 However, all medical therapies come with risks. Therefore, all 
patients should be evaluated prior to starting any pharmacotherapy 
or surgical treatment.
 Additionally, weight loss will not be effective at reducing patient 
health risks without the adoption of lifestyle changes. Thus, in 
addition to evaluating for health contraindications, patients should 
be educated on lifestyle changes and show that they have 
incorporated these into their life before medical therapies should be 
initiated. 
 As a clinician, it is imperative to provide support resources for the 
patient’s weight loss journey with extensive follow up to encourage 
continued efforts. 
 With these efforts on the patient and clinician’s behalf, it may be 
possible to increase success rates in the treatment of obesity.
Obesity is a rising epidemic, and is one of the most 
common, costly and preventable health problems the world 
is experiencing today (Center for Disease Control and 
Prevention, [CDC], 2017). 
 From this, it is important to establish an effective treatment plan that 
can be implemented across the nation for maximum patient benefit. 
 Lifestyle changes such as diet and exercise are important to any 
health care plan and are equally necessary to reduce health risks. 
However, in certain patients, lifestyle changes are not enough due 
to the maladaptive biologic process in their brain. Thus, additional 
treatment options need to be available to these patients. 
 Both medical therapies, pharmacological and surgical, were found 
to be beneficial in augmenting lifestyle changes in multiple studies. 
Therefore, it was concluded that pharmacologic and surgical 
therapies are valid options in resistant obesity in addition to lifestyle 
changes such as diet and exercise. 
 This study was a systematic literature review which evaluated studies from 
CINAHL, Clinical Key, Cochrane Library, and PubMed to formulate a 
conclusion. Research focused on two pharmacotherapy options, phentermine 
and orlistat, in addition to two surgical options, gastric bypass and sleeve 
gastrectomy, for added weight loss treatment when compared to lifestyle alone. 
.
Obesity has a multitude of comorbidities associated with it such as: 
HTN, hyperlipidemia, diabetes mellitus type 2, stroke, coronary artery 
disease, depression and others, including death. Therefore, it is 
important to evaluate studies regarding each treatment method’s 
effectiveness and long-term outcomes to better assess where more 
research should take place. 
 In obese populations, Body Mass Index (BMI) greater than or equal 
to 30, do drug therapies, such as phentermine and orlistat, 
provide better long-term health outcomes than lifestyle changes to 
diet and exercise patterns? 
 In obese populations, BMI greater than or equal to 30, do 
surgeries, such as gastric bypass and sleeve gastrectomy (SG), 
provide better long-term health outcomes than lifestyle changes to 
diet and exercise patterns?
 Alter et al. (2012) examined the cost of obesity on the Canadian 
health care system over 11.5 years. Obese individuals averaged 
about $8,294.67 per person when they had no other health related 
comorbidities, whereas their propensity matched normal weight 
counterparts costed $7,323.59 (p=0.27). When one negative 
health risk factor was added to an obese individual their additional 
cost rose to $2000 greater than their normal weight counterparts 
with similar comorbidities. When multiple risk factors were 
present, obese individuals cost increased $2700-$7000.  
 Moldovan et al. (2016) performed a highly controlled study where 
participants were given Medifast meal replacements and instructed 
to follow the Take Shape for Life Optimal Weight 5&1 Plan for 
weight loss and the Habits of Health program. There was a placebo 
group (no medication) and a phentermine HCl 37.5mg group. The 
phentermine group experienced a more substantial fat and 
sweet craving decrease (p=0.012 and 0.038). Participants in the 
phentermine group also yielded greater weight loss and BMI 
reduction with 12.1% weight loss when compared to the placebo 
group with an 8.8% weight loss (p=0.028). Specifically, phentermine 
participants lost 2.1% more fat than the placebo group with a p
value of 0.019.
 Samp, Al-Tahami, Ariffin, Omar, and Rasool (2015) evaluated a 9-
month study where patients were on orlistat 120 mg three times a 
day, and then reevaluated the patients again 4 months after 
cessation of orlistat by anthropometric parameters. Nine-months of 
orlistat treatment resulted in statistically significant decreases 
in total body weight, BMI, waist circumference, body and 
visceral fat percentage, total cholesterol, triglyceride, insulin 
levels and insulin resistance. There was continued 
cardiovascular benefit 4 months after cessation of orlistat.
 Foschi et al. (2018) evaluated an ileal interposition with duodenal 
diversion sleeve gastrectomy (II-DD-SG) to standard medical care in 
type two diabetic patients. II-DD-SG’s mean fasting plasma 
glucose (FPG) fell from 154.6 ± 6.4 to 89.6 ± 2.4 mg/dL and mean 
HbA1c from 7.7 ± 0.1% to 5.6 ± 0.2% six months after surgery. 
These results were stable throughout the five years of the study with 
p < 0.0001. In 86% of the surgical patients there was complete 
diabetic remission and 56% had remission of cardiovascular 
risk factors. Only two patients in the standard medical care group 
achieved complete remission of diabetes with no cardiovascular risk 
factor change.
 Chopra, Chao, Etkin, Merklinger, Lieb, and Delany (2011) also 
evaluated SG and its effects on health status. Chopra was able to 
find that 84% of their population had improvement in diabetic 
status, 49.99% had improvement in hypertension control, 90%
had better asthma control, 90.74% found improvements in their 
obstructive sleep apnea symptoms, and 45.92% had better 
control of their gastroesophageal reflux disease.
 Brandt, Clemensen, Nielsen, and Søndergaard (2018) found that 
30% of participants initiated a lifestyle change because their 
healthcare provider voiced concern about their health. 
Participants in this study also found it most effective to continue 
lifestyle changes when their healthcare professional showed 
interest in their self-measurements and when they made more 
achievable daily goals. 
 Shaw, Gennat, O’Rourke, and Del Mar (2006) of Cochrane 
systematic review found that exercise and diet combined, 
produced greater weight loss than exercise alone, with a 
weighted mean difference (WMD) of 1.0 kg and a confidence 
interval (CI) of 95%. Weight loss was also increased with 
increased intensity of exercise, WMD 1.5 kg and CI 95% (Shaw 
et al., 2006). Exercise also reduced diastolic blood pressure by 
an average of 2 mmHg with a 95% CI, reduced triglycerides by 0.2 
mmol/L with a 95% CI, and fasting serum glucose was found to 
have higher decreases with higher intensity workouts with a 0.3 
mmol/L reduction and a 95%. Additionally, 150 minutes of 
moderate exercise was shown to prevent weight gain, and 250 
minutes or greater produced significant weight loss.
 I would like to express my thanks to my advisor, Mindy 
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I would like to thank them both for their willingness to 
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 I would also like to thank Dawn Hackman, Dr. Marilyn Klug, 
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RD, LRD, CDE for their individual reviews of my project. 
Their personal expertise was vital to answering my research 
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 Finally, I would like to thank my family. Without their support 
and help for me to go back to school, none of this would 
have been possible. 
Applicability to Clinical 
Practice
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